Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

PCSK9 inhibitors

- PMLiVE

Amgen announces positive results for Lumakras colorectal cancer combination treatment

Results demonstrated a confirmed objective response rate of 30% and median progression free survival of 5.7 months

regeneron headquarters

Regeneron’s Libtayo shows promising results in phase 2 skin cancer trial

In the phase 2 trial, 50.6% of patients achieved the primary endpoint of complete pathologic response

- PMLiVE

Sanofi and Regeneron share positive data for asthma drug

The trial evaluated the drug for children aged six to 11 years with moderate-to-severe asthma

- PMLiVE

Amgen’s Lumakras shows promising results for patients with non-small cell lung cancer

Results from the phase 3 trial demonstrated superiority over standard of care Docetaxel chemotherapy in KRAS G12C-mutated non-small cell lung cancer

- PMLiVE

Sanofi and Sobi’s efanesoctocog alfa granted FDA priority review for haemophilia A

Phase 3 results showed once-weekly doses provided clinically meaningful bleed protection for patients with haemophilia A

- PMLiVE

Amgen announces positive results for Solaris biosimilar for paroxysmal nocturnal haemoglobinuria

ABP 959 demonstrated no ‘clinically meaningful’ difference to the reference product in the phase 3 study

- PMLiVE

Sanofi and NIHR enrol first patient in immunisation study for RSV in infants

RSV is the leading global cause of infant hospitalisation and affects 90% of children under the age of two

- PMLiVE

Sanofi halts recruitment for trials assessing MS treatment

The pause in enrolment follows advice issued by the Independent Data Monitoring Committee

- PMLiVE

Amgen to acquire ChemoCentryx in $3.7bn cash deal

The agreement includes the acquisition of ChemoCentryx’s autoimmune disease treatment Tavneos

- PMLiVE

Sanofi and Innovent Biologics to develop oncology drugs for patients in China

Sanofi will make an initial equity investment of €300m in Innovent

regeneron headquarters

Regeneron terminates four clinical trials of its COVID-19 antibody cocktail REGEN-COV

The drug was taken off the US market in January due to it being ‘highly unlikely’ to be active against the Omicron variant

- PMLiVE

Sanofi and Regeneron announce positive phase 3 trial results for eosinophilic oesophagi in children under 12

There are currently no approved treatments for children with eosinophilic oesophagi under the age of 12

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links